Damian Garde from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	What about the company Vertex didn’t buy? - 11 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 11 months ago Gas prices are hurting biotech - 11 months ago Pfizer’s plot to win the RSV vaccine race - 11 months ago What’s Congress going to do with WuXi? - 11 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 11 months ago Brazil’s plan for low-cost CAR-Ts - 11 months ago Merck’s next big thing is (probably) on the way - 11 months ago Listen: Live! From the STAT Breakthrough Summit East - 11 months ago STAT+: Regeneron’s plot to ‘cure’ allergies - 11 months ago Novo is building a really big computer - 11 months ago Wegovy and Zepbound get primetime treatment - 11 months ago STAT+: FDA advisers back CAR-T therapies in blood cancer, despite safety concerns - 11 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 12 months ago Is CAR-T safe for early-stage patients? - 12 months ago Geron’s resurgence might have been short-lived - 12 months ago When did Wall Street sour on Lilly’s Alzheimer’s drug? - 12 months ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 12 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 12 months ago Banning WuXi is more complicated than it might sound - 12 months ago Where’s Lilly’s Alzheimer’s approval? - 12 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 12 months ago The next act for a biotech rainmaker - 12 months ago The FDA isn’t afraid to yank a disappointing drug - 12 months ago Humira’s legacy, CEO symbolism, and genomic surgery - about 1 year ago Novavax’s money is going in the wrong direction - about 1 year ago Actually Wegovy is good for dialysis companies, dialysis provider says - about 1 year ago Bayer, short on cash, reaches into shareholders’ pockets - about 1 year ago Alnylam thickened the plot - about 1 year ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - about 1 year ago Listen: AI in medicine, detangling hype, and Icelandic DNA - about 1 year ago Gilead sours on the ‘don’t eat me’ business - about 1 year ago Vertex still knows how to do what it does best - about 1 year ago Eli Lilly overtakes Tesla in market value - about 1 year ago Listen: The plight of the VC, Gilead’s latest setback, & more M&A - about 1 year ago Another step toward new drugs for Parkinson’s - about 1 year ago Biotech layoffs, slumping stocks, and a 2024 preview - about 1 year ago The XBI comedown after JPM - about 1 year ago The highs — and lows — of JPM 2024 you should pay attention to - about 1 year ago Listen: Live! From JPM 2024 - about 1 year ago This is the TLDR of JPM Day 1 - about 1 year ago Why CG Oncology will be the first test of 2024’s IPO waters - about 1 year ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - about 1 year ago Anavex’s slow journey to failure - about 1 year ago STAT+: Cytokinetics heart drug aficamten succeeds in pivotal study - about 1 year ago STAT+: What comes after Wegovy? The quest to eradicate obesity - about 1 year ago STAT+: Bristol Myers will pay $4.1 billion for cancer startup RayzeBio - about 1 year ago The clock is ticking, and Cytokinetics is running out of December - about 1 year ago STAT+: FDA approves AstraZeneca, Ionis treatment for rare nerve disease - about 1 year ago Listen: 2023 in review, CEO report cards, and a look at the year ahead - about 1 year ago
2	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 11 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 11 months ago Listen: Live! From the STAT Breakthrough Summit East - 11 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 12 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 12 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 12 months ago Humira’s legacy, CEO symbolism, and genomic surgery - about 1 year ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - about 1 year ago Listen: AI in medicine, detangling hype, and Icelandic DNA - about 1 year ago Listen: The plight of the VC, Gilead’s latest setback, & more M&A - about 1 year ago Biotech layoffs, slumping stocks, and a 2024 preview - about 1 year ago The highs — and lows — of JPM 2024 you should pay attention to - about 1 year ago Listen: Live! From JPM 2024 - about 1 year ago This is the TLDR of JPM Day 1 - about 1 year ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - about 1 year ago Listen: 2023 in review, CEO report cards, and a look at the year ahead - about 1 year ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 11 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 11 months ago Listen: Live! From the STAT Breakthrough Summit East - 11 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 12 months ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 12 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 12 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 12 months ago Humira’s legacy, CEO symbolism, and genomic surgery - about 1 year ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - about 1 year ago Listen: AI in medicine, detangling hype, and Icelandic DNA - about 1 year ago Listen: The plight of the VC, Gilead’s latest setback, & more M&A - about 1 year ago Biotech layoffs, slumping stocks, and a 2024 preview - about 1 year ago The highs — and lows — of JPM 2024 you should pay attention to - about 1 year ago Listen: Live! From JPM 2024 - about 1 year ago This is the TLDR of JPM Day 1 - about 1 year ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - about 1 year ago Listen: 2023 in review, CEO report cards, and a look at the year ahead - about 1 year ago
4	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	The highs — and lows — of JPM 2024 you should pay attention to - about 1 year ago This is the TLDR of JPM Day 1 - about 1 year ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - about 1 year ago
5	Mohana Ravindranath STAT News Health tech reporter at STAT. Oakland, CA + Washington, D.C. Health techreporting	STAT+: Burning questions for the 2024 JPM Healthcare Conference - about 1 year ago
6	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: What comes after Wegovy? The quest to eradicate obesity - about 1 year ago
7	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: What comes after Wegovy? The quest to eradicate obesity - about 1 year ago